Tests IMG-007 doses in adults with moderate-to-severe atopic dermatitis
Tests different IMG-007 doses against placebo in adults with atopic dermatitis.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Key facts
- Where
- Augsburg, Bad Bentheim, Berlin, Darmstadt, Dresden, Frankfurt Am Main, Hamburg, Luebeck, Muenster, and Tuebingen, GermanySee the 10 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate-to-severe atopic dermatitis (eczema) who did not respond well to, or could not tolerate, topical treatments.
- Age
- 18 to 74 years
- Sex
- All sexes can join.
- Disease stage
- Moderate-to-severe atopic dermatitis: EASI score ≥16, vIGA-AD score ≥3, ≥10% of body surface area affected, and mean peak itch score ≥ 4 in the 7 days before randomization.
- Earlier treatment
- Must have had an inadequate response or poor tolerance to a stable regimen of one or more topical treatments before screening, or topical treatments are otherwise inadvisable.
Main reasons for not taking part
- Positive hepatitis B, hepatitis C, or HIV infection
- Active or latent tuberculosis, or past untreated or inadequately treated TB infection
- Active infection needing systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals
- Other active unstable itchy skin conditions that would interfere with assessing AD
- Pregnant or breastfeeding women
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 74 years old?
Source: NCT07037901, who can take part
Where in Germany
- Universitaetsklinikum AugsburgAugsburg, GermanyNot yet recruiting
- Thermalsole und Schwefelbad Bentheim GmbHBad Bentheim, GermanyNot yet recruiting
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyNot yet recruiting
- Rosenpark Research GmbhDarmstadt, GermanyNot yet recruiting
- Technische Universitaet DresdenDresden, GermanyNot yet recruiting
- Universitaetsklinikum Frankfurt AöRFrankfurt Am Main, GermanyNot yet recruiting
- Dermatologikum Hamburg GmbhHamburg, GermanyNot yet recruiting
- Universitaetsklinikum Schleswig-Holstein AöRLuebeck, GermanyNot yet recruiting
- Universitaet MuensterMuenster, GermanyNot yet recruiting
- Universitaetsklinikum Tuebingen AöRTuebingen, GermanyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Inmagene LLC
- Trial code
- NCT07037901EU 2024-520117-50-00
- Record updated
- 12 August 2026
- Original description
The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.Read full original descriptionShow less
A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.
Inclusion: Moderate-to-severe AD; Documented history of inadequate response or lack of tolerability to a stable regimen of one or more topical treatment before the Screening visit, or for whom topical treatments are otherwise inadvisable; Female participants who are not pregnant or breastfeeding and meet at least one of the following conditions: not of childbearing potential or of childbearing potential and agrees to use a highly effective method of contraception; Male participants must agree to use a highly effective method of contraception; EASI score ≥16; vIGA-AD score ≥3; ≥10% body surface area (BSA) of AD involvement; Mean peak pruritus numerical rating scale ≥ 4 during 7-days before randomization.
Exclusion: Active infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals; Having received any of the specified therapies within the specified timeframe(s) prior to the Baseline visit; Positive hepatitis B, hepatitis C, or human immunodeficiency virus infection; Evidence of active or latent tuberculosis (TB); History of untreated or inadequately treated TB infection; Active unstable pruritic skin conditions in addition to AD that would interfere with the assessment of AD based on the investigator's clinical judgement; Other conditions or laboratory abnormality that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study.